Refractory Bone Marrow Involvement Responding to Ribociclib and Tamoxifen in Advanced Breast Cancer

  • Manikandan DhanushkodiEmail author
  • Sridevi Velusamy
Case Report

A 64-year-old female was presented with bicytopenia and was diagnosed with carcinoma left breast, cT3N1M1 (bone marrow/bone/pleural effusion/leptomeningeal involvement). Histopathology showed infiltrating ductal carcinoma, grade 3, and immunohistochemistry showed ER (estrogen receptor) 90%; PR (progesterone receptor) 60%; HER2 neu 2 + and FISH (fluorescent in situ hybridization) for HER2 neu was negative. As she had bicytopenia (hemoglobin 6.8 gm/dl and platelet count 50,000 cells/mm3), she was treated with Inj. cyclophosphamide 500 mg weekly twice for 1 week followed by weekly paclitaxel 80 mg/m2 and intrathecal methotrexate. After six cycles of weekly paclitaxel, her blood counts recovered (hemoglobin 8.9 gm/dl and platelet count 105,000 cell/mm3). After 11 cycles of weekly paclitaxel, she had fatigue and decreased albumin (serum albumin 2.3 mg/dl) and was switched to Tab. letrozole 2.5 mg OD. She was intolerant to letrozole with grade 3 musculoskeletal pain and was switched to Tab....



Not applicable.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Shiozawa Y, Eber MR, Berry JE, Taichman RS. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. BoneKEy Rep. 2015;4:689. Scholar
  2. 2.
    Fan FS, Yang C-F, Wang Y-F. Diffuse bone marrow metastasis as the initial presentation of an occult breast cancer. Case Rep Oncol Med. 2018;2018:2946409. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zhou MH, et al. Clinical outcome of 30 patients with bone marrow metastases. J Cancer Res Ther. 2018;14:S512–5.CrossRefGoogle Scholar
  4. 4.
    Demir L, et al. Prognostic evaluation of breast cancer patients with evident bone marrow metastasis. Breast J. 2014;20:279–87.CrossRefGoogle Scholar
  5. 5.
    Kopp H-G, et al. Symptomatic bone marrow involvement in breast cancer–clinical presentation, treatment, and prognosis: a single institution review of 22 cases. Anticancer Res. 2011;31:4025–30.PubMedGoogle Scholar
  6. 6.
    Takayama S, et al. A case of bone marrow carcinomatosis from breast cancer treated with weekly Paclitaxel. Gan To Kagaku Ryoho. 2012;39:99–101.PubMedGoogle Scholar
  7. 7.
    Cahyanur R, Rinaldi I. Hormonal treatment for symptomatic bone marrow metastasis in breast cancer patients. Mædica. 2018;13:238–40.PubMedCentralGoogle Scholar
  8. 8.
    Xu L, et al. Trastuzumab monotherapy for bone marrow metastasis of breast cancer: a case report. Oncol Lett. 2014;7:1951–3.CrossRefGoogle Scholar
  9. 9.
    Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3638–46.CrossRefGoogle Scholar
  10. 10.
    Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.CrossRefGoogle Scholar
  11. 11.
    Hortobagyi GN, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48.CrossRefGoogle Scholar
  12. 12.
    Im S-A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019. Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Department of Surgical OncologyCancer Institute (WIA)ChennaiIndia

Personalised recommendations